Challenges and opportunities in NASH drug development.

Area of Science:

• Hepatology
• Clinical Pharmacology
• Translational Medicine

Background:

• Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are global health issues with no approved treatments.
• Liver biopsy is currently required for drug approval, posing significant challenges in clinical trials.

Purpose of the Study:

• To review the challenges in NAFLD-NASH drug development, focusing on the limitations of histopathological assessment.
• To discuss potential strategies and non-invasive tests to overcome these hurdles and advance therapeutic development.

Main Methods:

• Literature review of current drug development practices for NAFLD-NASH.
• Analysis of the role and limitations of liver biopsy as a primary endpoint.
• Exploration of non-invasive biomarkers and their regulatory acceptance.

Main Results:

• Histopathological assessment of liver biopsies shows significant variability, leading to high screen-failure rates in clinical trials.
• Non-invasive tests are being developed to correlate with liver histology but require more data for regulatory endorsement.
• Drug development for NAFLD-NASH is hindered by the reliance on invasive diagnostic methods.

Conclusions:

• Addressing the challenges in NAFLD-NASH clinical trials is crucial for advancing drug development.
• Further validation of non-invasive methods is needed to serve as reliable alternatives to liver biopsies.
• Implementing innovative trial designs and endpoints can accelerate the approval of new therapies for NAFLD-NASH.